Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis
Bong-Woo Lee, Jennifer Jooha Lee, Wan-Uk Kim
Korean J Intern Med. 2024;39(5):833-844. Published online 2024 May 27 DOI: https://doi.org/10.3904/kjim.2023.297
Citations to this article as recorded by 
Survival of first line biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in Chile
Marcos Cruces Olivar, Allan D. Burboa, Yolanda M. Gómez
Reumatología Clínica.2025; 21(8): 501946. CrossRef
Survival of first line biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in Chile
Marcos Cruces Olivar, Allan D. Burboa, Yolanda M. Gómez
Reumatología Clínica (English Edition).2025; 21(8): 501946. CrossRef
Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: A population-based cohort study
Po-Cheng Shih, Po-Cheng Hung, Pui-Ying Leong, Jui-Ning Hsu, Chieh-Chun Yang, James Cheng Chung Wei, Hsin-Hua Chen
Clinical Rheumatology.2024; 43(12): 3625. CrossRef